Oppenheimer analyst Kristen Owen raised the firm’s price target on Corteva (CTVA) to $72 from $70 and keeps an Outperform rating on the shares. The firm sees Corteva coming into 2025 with the benefits of its diversified portfolio, technology differentiation, and self-help drivers, positioning it for healthy 10% margin and earnings growth. The updated outlook was broadly in line with expectations, and Oppenheimer believes offers the potential for upside should stronger global trait penetration materialize.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.